BreastCancerTrials.org - find a trial that's right for you
Tour
Privacy
Donate
Contact Us
Follow Us
Twitter
Facebook
Home   HELP  /   AYUDA  /   求助 : bctrials@quantumleaphealth.org  /   (888) 282-7099 Click to print page  Print

Browse Trials

➤

Find Breast Cancer Clinical Trials That Are Right For You

The clinical trials listed below are open in the U.S. for people with DCIS (stage 0), stage 1, stage 2, stage 3, or stage 4 (metastatic)
breast cancer. Clinical trials are available for people who are newly diagnosed with breast cancer, currently in treatment, experiencing
breast cancer recurrence, living with metastatic disease, as well as breast cancer survivors who have completed treatment.

Use the search box and filters to find a trial that’s right for you.


Currently viewing trials
(Last updated: January 16, 2026)

Zip Code:
 

Narrow my choices:

Radius (miles): All U.S.

20 All U.S.
Early stage    Advanced 
Treatment    Non-treatment 
Phase    I     II     III 
Display Only New Trials 
 
Close
Treatment

Brain Mets

BRCA1/2 (inherited)

Chemotherapy

Hormone Therapy

Leptomeningeal Disease

Radiation Oncology

Surgery

Surgery: Reconstruction

Targeted Therapy: All

Targeted Therapy: ADC

Targeted Therapy: Anti-HER2 Therapy

Targeted Therapy: CDK Inhibitors

Targeted Therapy: PARP Inhibitors

Targeted Therapy: Tumor Mutations

Targeted Therapy: Other Targeted Therapy

Vaccines and Immunotherapy

Other Treatment

Non-Treatment

Activities

Complementary and Integrative Medicine

Decision Support

Diagnosing Breast Cancer

Genetics/Family History

Having Children

Healthy/High Risk

Imaging

Lymphedema

Managing Side Effects

No Travel Required

Predicting Response to Treatment

Preventing Breast Cancer

Preventing Recurrence

Support/Education

Surveys/Interviews/Registries

Close

AKT

ALK

AR

BARD1

BRCA1/2 (tumor)

BRIP1

CD205

CD70

CHEK2 or CHEK1

dMMR/MSI-H

ESR1

FGFR

HER2/ERBB2

HLA

MET or C-Met

NTRK

PALB2

PIK3CA or PI3K

PTEN

RAD51

RAF (including BRAF)

RAS (KRAS or NRAS)

RB

ROS1

TP53

1

NEAREST SITE: 3 miles
University of California San Francisco
San Francisco,CA

VISITS: Online surveys

PHASE: NA

NCT ID: NCT02620852

WISDOM Study: Women Informed to Screen Depending on Measures of Risk

Enabling a Paradigm Shift: A Preference-Tolerant RCT of Personalized vs. Annual Screening for Breast Cancer Scientific Title

Purpose
To learn if risk-based breast screening is as safe and effective as annual mammogram screening for reducing risk and detecting breast cancer.
Who is this for?
Women between the ages of 40 and 70 who have never been diagnosed with breast cancer or ductal carcinoma in situ (DCIS).    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will be randomly assigned to 1 of 2 groups, or you can choose your study group. </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1: Personalized, Risk-Based Screening</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Screening recommendations based on comprehensive, personal risk assessment</li> <li class="seamTextUnorderedListItem">Saliva sample genetic test</li> <li class="seamTextUnorderedListItem">Online, annual health questionnaires</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2: Standard Annual Screening</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Screening recommendation for annual mammograms</li> <li class="seamTextUnorderedListItem">Online, annual health questionnaires</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Personalized risk-based screening will take multiple risk factors into consideration, including genetic markers, to determine how often you should have a mammogram.</li> <li class="seamTextUnorderedListItem">This study will help researchers learn if risk-based screening, which helps women learn more about their personal breast cancer risk, is less stressful and as successful at detecting breast cancer as annual screening. </li> <li class="seamTextUnorderedListItem">This study is available in English and Spanish.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT02620852' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.thewisdomstudy.org/' target='_blank'>WISDOM: Study Information Page</a> </li></ul>
See more
2

NEAREST SITE: 22 miles
Contra Costa Regional Medical Center
Martinez,CA

VISITS: 2 visits in 1 year

PHASE: NA

NCT ID: NCT05334069

Collecting Blood Samples From People With and Without Breast Cancer to Evaluate Tests for Early Cancer Detection

Blinded Reference Set for Multicancer Early Detection Blood Tests Scientific Title

Purpose
To collect blood and tissue samples from people with breast cancer and people without breast cancer to evaluate tests for early cancer detection.
Who is this for?
People 40-75 years old with stage I, stage II, stage III, or stage IV (metastatic) breast cancer who have not yet received treatment, or who do not have breast cancer.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Provide blood samples, 2 times</li> <li class="seamTextUnorderedListItem">Provide tissue samples (for people with cancer), 2 times</li> <li class="seamTextUnorderedListItem">Complete questionnaires, 2 times</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Collecting and storing samples of blood and tissue from patients with and without breast cancer to study in the laboratory may help researchers develop tests for the early detection of cancers.</li> <li class="seamTextUnorderedListItem">This trial is also available in Spanish.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05334069' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/about-cancer/diagnosis-staging/diagnosis' target='_blank'>National Cancer Institute: How Cancer Is Diagnosed</a> </li></ul>
See more
3

NEAREST SITE: 22 miles
Redwood City
Redwood City,CA

VISITS: Number of visits unavailable

PHASE: NA

NCT ID: NCT05059444

ctDNA Test to Detect Breast Cancer That Has Come Back or Remains After Treatment

ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation (ORACLE) Scientific Title

Purpose
To study the ability of Guardant Reveal, a new blood test, to detect residual disease and recurrence after treatment.
Who is this for?
People with stage I, stage II, or stage III breast cancer who have residual disease (leftover cancer cells in your breast or lymph node) after chemotherapy and surgery.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Blood tests</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Circulating tumor DNA (ctDNA) are small pieces of cancer cell DNA in the bloodstream.</li> <li class="seamTextUnorderedListItem">Guardant Reveal is a new test that detects ctDNA in blood.</li> <li class="seamTextUnorderedListItem">Residual disease refers to cancer cells present after treatment.</li> <li class="seamTextUnorderedListItem">Recurrence refers to cancer that has come back after treatment.</li> <li class="seamTextUnorderedListItem">This study is enrolling people with other types of cancer.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05059444' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://medlineplus.gov/genetics/understanding/testing/circulatingtumordna/' target='_blank'>MedLine Plus: What is ctDNA?</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.guardanthealthamea.com/guardant-reveal/' target='_blank'>Guardant Health: The Guardant Reveal ctDNA Test</a> </li></ul>
See more
4

NEAREST SITE: 28 miles
Kaiser Permanente Medical Center
Vallejo,CA

VISITS: Number of visits unavailable

PHASE: NA

NCT ID: NCT06401421

ctDNA Blood Test to Predict Recurrence for Stage I-III Breast Cancer

EXActDNA-003 / NSABP B-64: Breast Cancer Clinical Validation Study to Predict Recurrence of High-Risk Early Breast Cancer Treated With Neoadjuvant Therapy Using a Bespoke Circulating Tumor DNA Assay to Detect Molecular Residual Disease Scientific Title

Purpose
To study the use of a ctDNA blood test to predict recurrence.
Who is this for?
People with stage I, stage II, or stage III breast cancer who are planning to receive neoadjuvant (before surgery) chemotherapy.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will provide the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Blood samples</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Circulating tumor DNA (ctDNA) are small pieces of cancer cell DNA in the bloodstream.</li> <li class="seamTextUnorderedListItem">The test being studied in this trial looks for <q>molecular residual disease</q> in the blood, which is when ctDNA is detected.</li> <li class="seamTextUnorderedListItem">Molecular residual disease may indicate that breast cancer is still present after treatment or has come back (recurrence).</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06401421' target='_blank'>ClinicalTrials.gov</a> </li></ul>
See more
5

NEAREST SITE: 28 miles
Kaiser Permanente-Division of Research
Pleasanton,CA

VISITS: 2 times within 1 year

PHASE: NA

NCT ID: NCT06995898

Multi-Cancer Detection Blood Test to Screen for Cancer for Healthy People and People with Stage 0 Breast Cancer

The Vanguard Study: Testing a New Way to Screen for Cancer Scientific Title

Purpose
To study how multi-cancer detection (MCD) tests may work as cancer screening tools.
Who is this for?
People, aged 45-75 years, without cancer. People with stage 0 (DCIS) breast cancer may enroll.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will be randomly assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1: Experimental</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">MCD blood test</li> <li class="seamTextUnorderedListItem">Review of your medical records</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2: Control</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Blood test</li> <li class="seamTextUnorderedListItem">Review of your medical records</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">A multi-cancer detection (MCD) test measures markers in the blood to screen for multiple cancers at the same time. MCDs may work as cancer screening tools.</li> <li class="seamTextUnorderedListItem">This study will assess how well MCD tests perform as cancer screening tools. It will also help researchers understand how patients and their doctors make decisions about their care when the MCD test result comes back normal or abnormal.</li> <li class="seamTextUnorderedListItem">You will be notified of any abnormal test results.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06995898' target='_blank'>ClinicalTrials.gov</a> </li></ul>
See more
6

NEAREST SITE: 336 miles
UCLA Kaiser Permanente Center for Health Equity
Los Angeles,CA

VISITS: Number of visits unavailable

PHASE: NA

NCT ID: NCT05298605

Faith in Action: Church-Based Education and Navigation to Increase Breast Cancer Screening in Korean Women

Faith in Action! A Cluster-Randomized Trial to Evaluate the Efficacy of a Church-based Navigation Model to Increase Breast Cancer Screening Among Korean Women in Los Angeles Scientific Title

Purpose
To study if the Faith in Action cancer screening education and navigation curriculum increases breast cancer screening among Korean American women.
Who is this for?
Korean women at least 45 years old who do not have breast cancer, have not received a screening mammogram in the last 2 years, and are members of participating Korean churches in Los Angeles, California.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will be randomly assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1: Experimental</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Faith in Action cancer screening education and navigation curriculum</li> <li class="seamTextUnorderedListItem">American Cancer Society Screening Guidelines pamphlet</li> <li class="seamTextUnorderedListItem">Questionnaires</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2: Standard of Care</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Presentation on physical activity and nutrition</li> <li class="seamTextUnorderedListItem">American Cancer Society Screening Guidelines pamphlet</li> <li class="seamTextUnorderedListItem">Questionnaires</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Faith in Action is a curriculum designed to deliver cancer education and increase motivation to participate in breast cancer screening through proven approaches such as one-on-one education, small media, and workshops.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05298605' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://ucla.clinicaltrials.researcherprofiles.org/trial/NCT05298605' target='_blank'>UCLA: Faith in Action</a> </li></ul>
See more
7

NEAREST SITE: 343 miles
Keck Medicine of USC Koreatown
Los Angeles,CA

VISITS: 1 visit

PHASE: NA

NCT ID: NCT06336928

Comparing Liquid Biopsy Results to Mammogram and Biopsy Results

A Validation Study to Determine Concordance of Liquid Biopsy and Breast Cancer Diagnosis Scientific Title

Purpose
To compare liquid biopsy results to mammogram and biopsy results.
Who is this for?
Women who have not been diagnosed with breast cancer and women with stage 0 (DCIS), stage I, stage II, or stage III breast cancer who have not started treatment or have completed treatment.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will provide the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Liquid biopsy blood test</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">A liquid biopsy is a blood test that can detect cancer cells.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06336928' target='_blank'>ClinicalTrials.gov</a> </li></ul>
See more
8

NEAREST SITE: 348 miles
Los Angeles County-USC Medical Center
Los Angeles,CA

VISITS: 1 visit

PHASE: I

NCT ID: NCT06171607

Contrast-Enhanced Ultrasound to Identify Breast Masses

Characterizing Breast Masses Using an Integrative Framework of Machine Learning and Radiomics Scientific Title

Purpose
To learn if using contrast-enhanced ultrasound (CEUS) will help to determine if an ultrasound-guided biopsy is necessary.
Who is this for?
Women who are planning to receive an ultrasound-guided biopsy.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Contrast-enhanced ultrasound (CEUS) scan with Lumason or DEFINITY contrast agent, by IV, 1 time</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Ultrasounds use sound waves to produce images of structures within your body without using radiation. Ultrasounds are widely used to diagnose many diseases in the body.</li> <li class="seamTextUnorderedListItem">A contrast-enhanced ultrasound (CEUS) is an ultrasound given with a contrast agent that helps improve images obtained from the scan.</li> <li class="seamTextUnorderedListItem">In this trial, Lumason and Perflutren are the contrast agents.</li> <li class="seamTextUnorderedListItem">The scan will take 1-1.5 hours.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06171607' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/screening-testing/breast-biopsy' target='_blank'>Breastcancer.org: Breast Biopsies</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.mayoclinic.org/drugs-supplements/perflutren-lipid-microsphere-intravenous-route/side-effects/drg-20067608?p=1' target='_blank'>Mayo Clinic: Perflutren Ultrasound Contrast Agent</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.mayoclinic.org/drugs-supplements/sulfur-hexafluoride-lipid-type-a-microspheres-injection-route-intravenous-route/side-effects/drg-20405988?p=1' target='_blank'>Mayo Clinic: Lumason Ultrasound Contrast Agent</a> </li></ul>
See more
9

NEAREST SITE: 353 miles
City of Hope
Duarte,CA

VISITS: 10 visits within 3 years

PHASE: NA

NCT ID: NCT05366881

Blood Test to Detect Cancer After Treatment for Stage I-III Breast Cancer

cfDNA Assay Multicenter Prospective Observational Validation for Early Cancer Detection, Minimal Residual Disease, and Relapse (CAMPERR) Scientific Title

Purpose
To evaluate the ability of a blood test to detect whether someone's cancer is gone after completing treatment or if it has returned before it can be detected with standard methods.
Who is this for?
People at least 40 years old with stage I, stage II, or stage III breast cancer who were diagnosed within the last 3 months or whose cancer came back within the last 5 years, and people who do not have breast cancer.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will provide the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Blood samples, 10 times within 3 years</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">When cancer cells die, they release DNA into the bloodstream. This DNA can be detected following a blood test. This is sometimes called a liquid biopsy.</li> <li class="seamTextUnorderedListItem">This trial is testing what detection or no detection of cancer cell DNA (cfDNA) means for the patient.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling healthy people and people with other types of cancer.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05366881' target='_blank'>ClinicalTrials.gov</a> </li></ul>
See more
10

NEAREST SITE: 602 miles
University of Utah Health Hospitals/Huntsman Cancer Institute Population Sciences
Salt Lake City,UT

VISITS: Number of visits unavailable

PHASE: NA

NCT ID: NCT06305312

Referral for Assistance with Basic Needs After an Abnormal Mammogram

Community Services Navigation to Advance Health Equity in Breast Cancer Screening (B-SINCERE) Scientific Title

Purpose
To study if connecting people to assistance with food, housing, utilities, and transportation increases follow-up after an abnormal mammogram result.
Who is this for?
People with an abnormal result after a mammogram who have not been diagnosed with breast cancer and need support with food, housing, utilities, and/or transportation. You must live in or near Salt Lake City, Utah.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will be randomly assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1: Experimental</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Referral to United Way of Salt Lake's community referral services (SINCERE)</li> <li class="seamTextUnorderedListItem">Questionnaires</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2: Usual Care</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Standard referral to community resources</li> <li class="seamTextUnorderedListItem">Questionnaires</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Women with greater need for food, housing, utilities, and transportation are about half as likely to follow up after an abnormal mammogram than women without such needs.</li> <li class="seamTextUnorderedListItem">This trial is studying the United Way of Salt Lake's community referral services (SINCERE) intervention, which connects people to assistance with these needs.</li> <li class="seamTextUnorderedListItem">This trial is also available in Spanish.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06305312' target='_blank'>ClinicalTrials.gov</a> </li></ul>
See more
11

NEAREST SITE: 682 miles
Fred Hutch/University of Washington Cancer Consortium
Seattle,WA

VISITS: 5 visits within 6 months or 1 year

PHASE: I-II

NCT ID: NCT06502691

[18F]FTT Radiotracer to Detect Response to PARP Inhibitors on a PET Scan for Metastatic Breast Cancer

[18F]FTT Positron Emission Tomography (PET) in Patients With Metastatic Breast Cancer Scientific Title

Purpose
To study how well fluorine F 18 fluorthanatrace ([18F]FTT) radiotracer works in a PET scan to detect the response to PARP inhibitors.
Who is this for?
People with metastatic (stage IV) breast cancer who are planning to receive olaparib (Lynparza®) or talazoparib (Talzenna®) PARP inhibitor.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06502691' target='_blank'>ClinicalTrials.gov</a> </li></ul>
See more
12

NEAREST SITE: 752 miles
University of Arizona
Tucson,AZ

VISITS: 1 visit

PHASE: NA

NCT ID: NCT03954431

Breast Computed Tomography (CT) Scan for Healthy or High-Risk Women

Study of High-resolution, Lower Dose Dedicated Breast CT. Scientific Title

Purpose
To study if a new type of breast scan called dedicated breast CT or BCT can see small structures in the breast clearly and diagnose breast cancer more accurately.
Who is this for?
Women, age 40 years and older, who are planning to receive a breast scan or a breast biopsy.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Breast CT scan</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">The breast CT device will take multiple pictures of the person's breast and create a 3D image of the breast. It does not compress or squash the breast like a mammogram.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03954431' target='_blank'>ClinicalTrials.gov</a> </li></ul>
See more
13

NEAREST SITE: 1331 miles
Hendrick Health - Vera West Women's Center
Abilene,TX

VISITS: 1 visit

PHASE: NA

NCT ID: NCT06643767

Bexa Breast Exam for Breast Cancer Screening

Evaluation of the Bexa Breast Examination (BBE) As an Effective Solution to Breast Cancer Early Detection Scientific Title

Purpose
To compare the Bexa™ Breast Exam to the standard of care (mammogram) for detecting masses and breast cancer.
Who is this for?
Women 30-75 years old who are planning to receive a mammogram.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will receive the following, together called the Bexa™ Breast Exam: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Scan with the Bexa™ device</li> <li class="seamTextUnorderedListItem">Ultrasound scan</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">The Bexa™ device uses highly accurate pressure sensors to study breast tissue. It is low cost, portable, and does not use radiation.</li> <li class="seamTextUnorderedListItem">Bexa™ may be better for identifying breast masses than a standard of care mammogram.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06643767' target='_blank'>ClinicalTrials.gov</a> </li></ul>
See more
14

NEAREST SITE: 1615 miles
Mayo Clinic in Rochester
Rochester,MN

VISITS: 1-2 visits within 6 months

PHASE: NA

NCT ID: NCT06058650

Molecular Breast Imaging to Guide Biopsy

Pilot Clinical Study to Evaluate Molecular Breast Imaging- Guidance for Sampling of Breast Abnormalities Scientific Title

Purpose
To study how well molecular breast imaging (MBI) helps guide the collection of cells during a breast biopsy.
Who is this for?
Women who previously received breast imaging with mammography, ultrasound, MRI, or molecular breast imaging (MBI).    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will be assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1: Biopsy Not Recommended or Previous Imaging/Biopsy Showed Benign (Normal) Results</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Technetium Tc-99m sestamibi, by IV, 1 time</li> <li class="seamTextUnorderedListItem">Molecular breast imaging (MBI), 1 time</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2: Biopsy Recommended</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Technetium Tc-99m sestamibi, by IV, 1 time</li> <li class="seamTextUnorderedListItem">Molecular breast imaging (MBI), 1 time</li> </ul> <p class="seamTextPara"> followed by: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Breast biopsy</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Collection of abnormal cells during a biopsy is often guided by either ultrasound or mammography in order to ensure that a sample of the correct part of the breast is taken.</li> <li class="seamTextUnorderedListItem">Sometimes abnormal tissue cannot be seen on ultrasound or mammography, and therefore, a biopsy guided with ultrasound or mammography may not always be accurate.</li> <li class="seamTextUnorderedListItem">Molecular breast imaging (MBI) is a method for detecting abnormal cells on a scan that uses injection of a radioactive tracer. Breast cancer cells take up this tracer more than normal cells, and this allows doctors to see the cancer cells on a scan.</li> <li class="seamTextUnorderedListItem">Technetium Tc-99m sestamibi is the tracer used in this study.</li> <li class="seamTextUnorderedListItem">MBI may improve the detection of some breast tumors.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06058650' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/screening-testing/molecular-breast-imaging' target='_blank'>Breastcancer.org: Molecular Breast Imaging</a> </li></ul>
See more
15

NEAREST SITE: 1615 miles
Mayo Clinic in Rochester
Rochester,MN

VISITS: Up to 5 visits in 1 year

PHASE: NA

NCT ID: NCT04799535

Ultrasound Scans to Diagnose Breast Cancer and Monitor Response to Treatment for Stage I-III Breast Cancer

Quantitative Microvasculature Imaging for Breast Cancer Detection and Monitoring Scientific Title

Purpose
To study how well breast ultrasound scans can diagnose breast cancer and measure response to treatment.
Who is this for?
People who are planning to receive or have received a breast biopsy, and people with stage I, stage II, or some stage III breast cancer who are planning to receive chemotherapy and/or hormone therapy before surgery (neoadjuvant).    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Breast ultrasound scan, up to 5 times in 1 year</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Ultrasounds use sound waves to produce images of structures within your body.</li> <li class="seamTextUnorderedListItem">Diagnostic procedures, such as breast ultrasound, may help find and diagnose breast cancer and may help measure response to earlier treatment.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04799535' target='_blank'>ClinicalTrials.gov</a> </li></ul>
See more
16

NEAREST SITE: 1615 miles
Mayo Clinic in Rochester
Rochester,MN

VISITS: 1 visit

PHASE: NA

NCT ID: NCT04692818

Ultrasound Scan to Diagnose Breast Masses Before Biopsy

3D Multimodal Ultrasound Imaging for Breast Cancer Scientific Title

Purpose
To study how well a new ultrasound imaging method works to diagnose breast masses.
Who is this for?
Women with a breast mass who are planning to receive a biopsy.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Ultrasound scan</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Ultrasounds use sound waves to produce images of structures within your body.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04692818' target='_blank'>ClinicalTrials.gov</a> </li></ul>
See more
17

NEAREST SITE: 1643 miles
M D Anderson Cancer Center
Houston,TX

VISITS: Number of visits unavailable

PHASE: NA

NCT ID: NCT05667532

Contrast-Enhanced Mammograms for Women with Dense Breasts

The C-MERIT Screening Cohort: Contrast-enhanced Mammography for Breast Cancer Screening and Risk Assessment in Women With Dense Breasts Scientific Title

Purpose
To compare the ability of contrast-enhanced mammography (CEM) and standard mammography to detect breast cancer in women with dense breasts.
Who is this for?
Women ages 30 to 75 with dense breasts and no personal history of DCIS or breast cancer.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Contrast-enhanced mammogram</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Please contact research site for treatment schedule</i></p>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Standard mammography (mammogram) is a breast cancer screening procedure involving taking an X-ray picture of the breast.</li> <li class="seamTextUnorderedListItem">Contrast-enhanced mammography (CEM) includes an injection of contrast dye before the mammogram to detect and visualize cancer cells.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05667532' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://uvahealth.com/services/breast-screening/cem' target='_blank'>University of Virginia Health: Contrast-Enhanced Mammogram</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cdc.gov/cancer/breast/basic_info/mammograms.htm' target='_blank'>Centers for Disease Control and Prevention: Mammogram</a> </li></ul>
See more
18

NEAREST SITE: 1643 miles
M D Anderson Cancer Center
Houston,TX

VISITS: 2 visits within 3 months

PHASE: NA

NCT ID: NCT05056844

Mammogram with Contrast to Detect Breast Cancer in Women with Abnormal Nipple Discharge

Contrast Enhanced Spectral Mammography (CESM) for the Evaluation of Pathologic Nipple Discharge: A Pilot Study Scientific Title

Purpose
To learn if contrast enhanced spectral mammography (CESM) is better than standard mammography for determining the cause of nipple discharge and detecting breast cancer.
Who is this for?
Women with abnormal fluid coming from the nipple (discharge) who receive care at MD Anderson Cancer Center in Houston, TX. You must not have been diagnosed with breast cancer.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Contrast enhanced spectral mammography (CESM)</li> <li class="seamTextUnorderedListItem">Digital tomosynthesis mammography</li> <li class="seamTextUnorderedListItem">Questionnaires</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">A mammogram is a breast cancer screening procedure involving taking an x-ray picture of the breast.</li> <li class="seamTextUnorderedListItem">Mammograms can identify areas of concern, but many areas (lesions) turn out to not be cancer.</li> <li class="seamTextUnorderedListItem">Contrast enhanced spectral mammography (CESM) is similar to standard mammography, but it includes an intravenous (by vein) injection of contrast, which makes tissue and blood vessels more visible in scans.</li> <li class="seamTextUnorderedListItem">CESM may increase the chance of finding breast cancers and decrease unnecessary biopsies.</li> <li class="seamTextUnorderedListItem">A breast tomosynthesis (DBT) mammogram takes multiple pictures of your breast from more angles than a standard mammogram.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05056844' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.mdanderson.org/cancerwise/what-is-a-contrast-enhanced-mammogram.h00-159701490.html' target='_blank'>MD Anderson Cancer Center: What is a Contrast-Enhanced Mammogram?</a> </li><li class='seamTextUnorderedListItem'><a href='https://my.clevelandclinic.org/health/diagnostics/15939-digital-breast-tomosynthesis-and-breast-cancer-screening' target='_blank'>Cleveland Clinic: Breast Tomosynthesis</a> </li></ul>
See more
19

NEAREST SITE: 1643 miles
Baylor College of Medicine
Houston,TX

VISITS: Coincides with biopsy

PHASE: NA

NCT ID: NCT06085833

New Method to Analyze Biopsy Tissue and Diagnose Breast Cancer

ARTIDIS Nanomechanical Generated Measurements for Early Breast Lesions (ANGEL) Scientific Title

Purpose
To study the ability of ARTIDIS ART-1 device, an experimental method of examining biopsy tissue, to predict tumor type, aggressiveness, and response to neoadjuvant (before surgery) treatment.
Who is this for?
People who are planning to receive a breast biopsy.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Breast biopsy analyzed with ARTIDIS ART-1 device</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">The standard method of examining tissue from a breast biopsy for the presence of cancer cells is to stain the tissue and look at it with a microscope.</li> <li class="seamTextUnorderedListItem">The ARTIDIS platform being tested in this study examines the physical properties and may reduce the amount of time for results.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06085833' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://artidis.com/' target='_blank'>ARTIDIS Biopsy Platform</a> </li></ul>
See more
20

NEAREST SITE: 1643 miles
The University of Texas MD Anderson Cancer Center
Houston,TX

VISITS: 3 visits within 2 years

PHASE: NA

NCT ID: NCT05625659

Imaging to Improve Breast Cancer Screening in Women With Dense Breasts

Comparison of Breast Cancer Screening With Dual-Energy Contrast-Enhanced Spectral Mammography to Digital Breast Tomosynthesis in Women With Dense Breasts (Contrast Mammography Imaging Screening Trial Scientific Title

Purpose
To study if dual-energy contrast-enhanced spectral mammography (CESM) can improve breast cancer screening in women with dense breasts.
Who is this for?
Women 45-74 years old with dense breasts.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Standard mammogram, 2 times within 1 year</li> <li class="seamTextUnorderedListItem">Contrast-enhanced spectral mammography (CESM), 2 times within 1 year</li> <li class="seamTextUnorderedListItem">Imaging contrast, by IV, 2 times within 1 year</li> </ul> <p class="seamTextPara"> followed by: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Email, text, or phone call</li> <li class="seamTextUnorderedListItem">Return to standard mammography for breast cancer screening</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Dual-energy contrast-enhanced spectral mammography (CESM) uses contrast to improve detection of breast cancer compared to standard mammograms.</li> <li class="seamTextUnorderedListItem">Some cancers, such as those present in dense breast tissue, may be visible on CESM but not on a standard mammogram.</li> <li class="seamTextUnorderedListItem">Breast cancer is harder to see on a mammogram of dense breasts.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05625659' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://densebreast-info.org/screening-technologies/contrast-enhanced-mammography/#:~:text=CEM%20can%20be%20used%20to,or%20abnormalities%20seen%20on%20mammograms.' target='_blank'>Dense Breast Info.org: Contrast-Enhanced Mammograms</a> </li><li class='seamTextUnorderedListItem'><a href='https://densebreast-info.org/for-patients/5-facts-you-should-know/' target='_blank'>Dense Breast Info.org: What to Know About Dense Breasts</a> </li></ul>
See more
21

NEAREST SITE: 1643 miles
M D Anderson Cancer Center
Houston,TX

VISITS: 2 visits within 2 weeks

PHASE: NA

NCT ID: NCT05042687

Molecular Breast Imaging Scan for Women at High Risk of Breast Cancer

Comparative Performance of Molecular Breast Imaging (MBI) to Magnetic Resonance Imaging (MRI) of the Breast in Identifying and Excluding Breast Carcinoma in Women at High Risk for Breast Cancer Scientific Title

Purpose
To compare the accuracy of molecular breast imaging (MBI) to breast magnetic resonance imaging (MRI) to detect breast cancer.
Who is this for?
Women at high risk for breast cancer who are planning to receive a breast MRI.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Breast MRI scan, 1 time</li> </ul> <p class="seamTextPara"> followed 2 weeks later by: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Molecular breast imaging (MBI) scan with technetium99m (Tc99m), by IV, 1 time</li> <li class="seamTextUnorderedListItem">Questionnaires, 2 times</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Molecular breast imaging (MBI) is a method for detecting abnormal cells on a scan that uses injection of a radioactive tracer. Breast cancer cells take up this tracer more than normal cells, and this allows doctors to see the cancer cells on a scan.</li> <li class="seamTextUnorderedListItem">A magnetic resonance imaging (MRI) scan produces body pictures created by using magnetic energy rather than x-ray energy.</li> <li class="seamTextUnorderedListItem">Technetium99m (Tc99m) is the tracer used in this study.</li> <li class="seamTextUnorderedListItem">If you do not speak English, an interpreter will help you translate.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05042687' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.mayoclinic.org/tests-procedures/molecular-breast-imaging/about/pac-20394710' target='_blank'>Mayo Clinic: Molecular Breast Imaging</a> </li></ul>
See more
22

NEAREST SITE: 1643 miles
MD Anderson Cancer Center
Houston,TX

VISITS: 1-2 visits

PHASE: NA

NCT ID: NCT06373354

Comparing 2 Types of Mammograms to Detect Changes in the Breast

Comparison of Conspicuity of Masses and Architectural Distortions Between Wide- and Narrow-angle Digital Breast Tomosynthesis Systems Scientific Title

Purpose
To compare the ability of 2 types of mammograms to detect changes in the breast.
Who is this for?
Women who are planning to receive a mammogram at MD Anderson Cancer Center.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Digital breast tomosynthesis (DBT), 1-2 times</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Digital breast tomosynthesis (DBT) is an advanced mammogram that takes multiple pictures of your breast from more angles than a standard mammogram.</li> <li class="seamTextUnorderedListItem">Of the 2 different types of DBT mammograms, 1 may be better than the other for detecting changes in the breast.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06373354' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://my.clevelandclinic.org/health/diagnostics/15939-digital-breast-tomosynthesis-and-breast-cancer-screening' target='_blank'>Cleveland Clinic: Digital Breast Tomosynthesis</a> </li></ul>
See more
23

NEAREST SITE: 1832 miles
Medical College of Wisconsin
Milwaukee,WI

VISITS: Number of visits unavailable

PHASE: NA

NCT ID: NCT06383026

Understanding Breast Cancer Screening Experiences for Transgender and Gender-Diverse People

Understanding Breast Cancer Risk and Screening in Transgender and Gender-Diverse Persons Through a Pilot Breast Cancer Screening Program Scientific Title

Purpose
To study the breast cancer screening perceptions and experiences of transgender and gender-diverse people and understand factors that make breast cancer screening more difficult.
Who is this for?
Transgender and gender-diverse people at least 30 years old who have received gender-affirming hormone therapy. You must not have a history of breast cancer or a known genetic mutation that increases your risk for breast cancer.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Mammogram</li> <li class="seamTextUnorderedListItem">Whole breast ultrasound</li> <li class="seamTextUnorderedListItem">Surveys</li> <li class="seamTextUnorderedListItem">Interviews</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Transgender and gender-diverse people may experience barriers and non-equitable treatment by healthcare professionals that make receiving breast cancer screening more difficult.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06383026' target='_blank'>ClinicalTrials.gov</a> </li></ul>
See more
24

NEAREST SITE: 1853 miles
Mile Square Health Center
Chicago,IL

VISITS: 3 visits

PHASE: NA

NCT ID: NCT05841355

Empowering Latina Women to Receive Breast Cancer Screening

Empowering Latinas to Obtain Guideline Concordant Screenings Scientific Title

Purpose
This trial will study a new way to educate Latina women about the importance of breast cancer screening.
Who is this for?
Latina women 50-74 years old who have not had a mammogram in the last 2 years and have not been diagnosed with breast cancer.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will be randomly assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1: Experimental</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">New breast cancer screening education, 3 sessions</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2: Control</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Standard breast cancer screening education, 3 sessions</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Please contact research site for trial schedule</i></p>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Latina women are less likely than other groups to receive breast cancer screening.</li> <li class="seamTextUnorderedListItem">Education sessions cover topics such as breast cancer information, screening, personal stories, lifestyle factors, role playing, and individual action plans.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05841355' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.bcrf.org/blog/hispanic-latina-breast-cancer-facts-statistics/' target='_blank'>Breast Cancer Research Foundation: Breast Cancer and Screening in Latina Women</a> </li></ul>
See more
25

NEAREST SITE: 2108 miles
Ohio State University Comprehensive Cancer Center
Columbus,OH

VISITS: Number of visits unavailable

PHASE: NA

NCT ID: NCT06666192

Cancer Screening and Education for Women in Central Ohio

A Multi-Level Intervention for Improving Screening Rates of Breast, Cervical and Colorectal Cancer in Women in Low-Income Communities Scientific Title

Purpose
To study how well the SCREEN Community Program increases cancer screening for low income and un/underinsured women in Central Ohio.
Who is this for?
Women who live in Central Ohio who are low income and do not have insurance (uninsured) or do not have enough insurance (underinsured).    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will receive the following as part of the SCREEN Community Program: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Cancer screening and follow-up</li> <li class="seamTextUnorderedListItem">Cancer screening educational materials</li> <li class="seamTextUnorderedListItem">Screening recommendations, by mail and during in-person visits</li> <li class="seamTextUnorderedListItem">Access to educational website</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">This trial involves screening for breast, cervical, and colorectal cancer.</li> <li class="seamTextUnorderedListItem">Cancer screening can detect cancer when treatment is less intensive and more successful.</li> <li class="seamTextUnorderedListItem">However many low income and un/underinsured women do not have access to health care and screenings.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06666192' target='_blank'>ClinicalTrials.gov</a> </li></ul>
See more
26

NEAREST SITE: 2108 miles
Ohio State University Comprehensive Cancer Center
Columbus,OH

VISITS: At least 1 visit

PHASE: NA

NCT ID: NCT04022616

Studying Immune Cells in Women with Stage I-IV Breast Cancer

Myeloid-Derived Suppressor Cell Function in Breast Cancer Patients Scientific Title

Purpose
To study immune cells involved in breast cancer.
Who is this for?
Women with stage I, stage II, or stage III breast cancer who have not yet received surgery, or women with stage IV (metastatic) breast cancer. You must be receiving care at the Ohio State Comprehensive Cancer Center or Stefanie Spielman Comprehensive Breast Center.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will provide the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Blood sample</li> <li class="seamTextUnorderedListItem">Tumor and/or lymph node samples (if removed during surgery)</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Natural killer (NK) cells are immune cells that identify and kill cancer cells.</li> <li class="seamTextUnorderedListItem">Myeloid derived suppressor cells (MDSC) are immune cells that kill NK cells, which helps cancer cells grow.</li> <li class="seamTextUnorderedListItem">In this study, researchers will look for and study these types of immune cells in the blood, tumor, and/or lymph node samples.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04022616' target='_blank'>ClinicalTrials.gov</a> </li></ul>
See more
27

NEAREST SITE: 2139 miles
Emory University Hospital/Winship Cancer Institute
Atlanta,GA

VISITS: 1-2 visits in up to 6 years

PHASE: NA

NCT ID: NCT06760507

Education and Screening for Cancers Related to BRCA for Women in Southwest Georgia

Evaluating an Evidence-Based Family History Screening Program Adapted to Increase Reach and Uptake of Screening for BRCA-Associated Cancers in Rural Public Health Clinics (RSPH5973-23) Scientific Title

Purpose
To study the ability of the GA CORE family history screening program to increase screening for cancers related to the BRCA gene.
Who is this for?
Women at least 25 years old who receive care in southwest Georgia.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will be randomly assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1: Experimental</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Education about breast cancer risk</li> <li class="seamTextUnorderedListItem">Follow up to encourage cancer screening (if recommended)</li> <li class="seamTextUnorderedListItem">Standard genetic testing results and follow up</li> <li class="seamTextUnorderedListItem">Surveys</li> <li class="seamTextUnorderedListItem">Interviews</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2: Usual Care</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Help from nurses about screening</li> <li class="seamTextUnorderedListItem">Standard genetic testing results and follow up</li> <li class="seamTextUnorderedListItem">Surveys</li> <li class="seamTextUnorderedListItem">Interviews</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Simple, low cost family history screening can identify families at high risk for cancers related to the BRCA gene.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06760507' target='_blank'>ClinicalTrials.gov</a> </li></ul>
See more
28

NEAREST SITE: 2240 miles
The Howard Center for Women's Health
Tifton,GA

VISITS: 2 visits in 1 month

PHASE: NA

NCT ID: NCT05036096

Cone Beam CT Imaging Scans for Breast Cancer Screening and Diagnosis

Cone Beam Breast CT for Breast Cancer Screening Scientific Title

Purpose
To study the usefulness of cone beam CT scans for breast screening and diagnosis.
Who is this for?
Women at least 40 years old who are planning to receive a screening mammogram, or women at least 30 years old who are planning to receive a diagnostic mammogram.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Mammogram</li> </ul> <p class="seamTextPara"> followed within 1 month by: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Cone beam CT scan</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">This trial is studying cone beam CT scans, a type of imaging scan that is obtained with a similar x-ray exposure as a standard mammogram.</li> <li class="seamTextUnorderedListItem">During a cone beam CT scan, you lay stomach-down on the exam table, and the image of your breast is obtained in a few seconds.</li> <li class="seamTextUnorderedListItem">A previous study showed that this imaging method results in better breast images than a standard mammogram.</li> <li class="seamTextUnorderedListItem">This study is finding additional information about the usefulness of this type of scan.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05036096' target='_blank'>ClinicalTrials.gov</a> </li></ul>
See more
29

NEAREST SITE: 2252 miles
UPMC Magee at the Lemieux Sports Complex
Cranberry Township,PA

VISITS: 3 visits in 4 years

PHASE: NA

NCT ID: NCT06105749

Contrast-Enhanced Mammograms After Treatment for Women with Stage 0-III Breast Cancer

Outcome of Biennial Screening Contrast-Enhanced Mammography (CEM) in Women With a Personal History of Breast Cancer (PHBC) Scientific Title

Purpose
To study if contrast-enhanced mammograms every other year in addition to standard of care mammograms every year improve breast cancer detection.
Who is this for?
Women 30-79 years old with stage 0 (DCIS), stage I, stage II, or stage III breast cancer who completed treatment at least 1 year ago.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Contrast-enhanced mammograms, 3 times in 4 years</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">You will also receive your regularly scheduled yearly mammograms while in this study.</li> <li class="seamTextUnorderedListItem">Contrast-enhanced mammograms are FDA-approved scans that are used in addition to regular mammograms and ultrasound scans.</li> <li class="seamTextUnorderedListItem">Contrast-enhanced mammograms are similar to standard mammograms but include an IV injection of contrast, which makes tissue and blood vessels more visible in scans.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06105749' target='_blank'>ClinicalTrials.gov</a> </li></ul>
See more
30

NEAREST SITE: 2299 miles
Roswell Park Cancer Institute
Buffalo,NY

VISITS: 1 visit

PHASE: NA

NCT ID: NCT03897270

Photoacoustic Imaging (A Scan That Uses Waves and Light) to Study Breast Tissue and Tumors in Women

Photoacoustic Imaging of Human Breast Scientific Title

Purpose
To study breast tissue and tumors by using photoaccoustic imaging (a type of scan that uses sound and light to study tissue).
Who is this for?
Women diagnosed with stage I, stage II, stage III, or stage IV (metastatic) breast cancer who have received or are planning to receive a breast MRI. You may also enroll if you have not been diagnosed with breast cancer but are scheduled to receive an MRI to look at a suspicious mass (lump) in your breast.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Photoacoustic imaging of the breast, for about 30 minutes, once</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">You may choose to repeat this process up to 10 times (on separate days)</i></p>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Research shows that mammograms are more difficult to read in women with dense breasts.</li> <li class="seamTextUnorderedListItem">Photoacoustic imaging is a type of scan that uses sound and light to study breast tissue.</li> <li class="seamTextUnorderedListItem">Researchers are studying whether photoacoustic imaging makes it easier to see tumors in women with dense breasts.</li> <li class="seamTextUnorderedListItem">They are also studying if they can learn anything new about breast tissue and tumors with this experimental imaging technique.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03897270' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://en.wikipedia.org/wiki/Photoacoustic_imaging' target='_blank'>Wikipedia: Photoacoustic Imaging</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/types/breast/breast-changes/dense-breasts' target='_blank'>NCI Breast Cancer: Dense Breasts</a> </li><li class='seamTextUnorderedListItem'><a href='https://dmm.biologists.org/content/12/7/dmm039636' target='_blank'>Journal Article: Photoacoustic Imaging as a Tool to Probe the Tumour Microenvironment</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7005545/' target='_blank'>Journal Article: Photoacoustic Imaging of Breast Cancer</a> </li></ul>
See more
31

NEAREST SITE: 2299 miles
Levine Cancer Institute
Charlotte,NC

VISITS: 1 visit every month for 4-6 months

PHASE: NA

NCT ID: NCT04174742

Questionnaires to Study Pain During Chemotherapy for Women with Stage I-III Breast Cancer

Self-Reported Pain and Nadir White Blood Cell/Absolute Neutrophil Count in Women 45 and Under Compared to Older Women Receiving Pegfilgrastim (or Biosimilar Substitution) While Undergoing Chemotherapy for Non-Metastatic Breast Cancer Scientific Title

Purpose
To study if younger women experience pain during treatment with chemotherapy and pegfilgrastim (Neulasta®) more often and/or at higher levels than older women.
Who is this for?
Women with stage I, stage II, or stage III breast cancer who are planning to receive chemotherapy and pegfilgrastim (Neulasta®).    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Questionnaires about pain</li> <li class="seamTextUnorderedListItem">Blood test, monthly for 4-6 months</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Pegfilgrastim (Neulasta®) is given to help prevent infections in people who are receiving some types of chemotherapy.</li> <li class="seamTextUnorderedListItem">This trial is also available in Spanish.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04174742' target='_blank'>ClinicalTrials.gov</a> </li></ul>
See more
32

NEAREST SITE: 2325 miles
Hawaii Radiology Associates, LTD (East Hawaii Women's Imaging Center)
Hilo,HI

VISITS: 1 visit

PHASE: NA

NCT ID: NCT05369546

Improving Digital Breast Tomosynthesis to Better Identify Breast Lesions That Require a Biopsy

Lesion Composition and Quantitative Imaging Analysis on Breast Cancer Diagnosis Scientific Title

Purpose
To improve the use of digital breast tomosynthesis (DBT) to better identify suspicious breast lesions that need to be biopsied.
Who is this for?
Women with a suspicious area on a mammogram who have not yet had a biopsy. You must not have a history of breast cancer.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Digital breast tomosynthesis (DBT), 1 time</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Most breast biopsies (71%) in the US do not result in a diagnosis of cancer. This means that many biopsies are unnecessary.</li> <li class="seamTextUnorderedListItem">A new way to use digital breast tomosynthesis (DBT) may reduce unnecessary biopsies.</li> <li class="seamTextUnorderedListItem">Digital breast tomosynthesis (DBT) is an advanced mammogram that takes multiple pictures of your breast from more angles than a standard mammogram.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05369546' target='_blank'>ClinicalTrials.gov</a> </li></ul>
See more
33

NEAREST SITE: 2376 miles
UVA Breast Care Center
Charlottesville,VA

VISITS: 1 visit

PHASE: NA

NCT ID: NCT04904757

Contrast-Enhanced Mammograms for Breast Cancer Screening

Willingness of Women to Undergo a Contrast-enhanced Spectral Mammography (CESM) for Breast Cancer Screening and Their Experience Before and After CESM Scientific Title

Purpose
To study if women receive contrast enhanced spectral mammograms (CESM) as their yearly breast screening test instead of standard of care mammograms.
Who is this for?
Women 40-69 years old who have mammogram results showing dense breasts within the last 2 years and are planning to receive a screening mammogram.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Contrast-enhanced spectral mammography (CESM)</li> <li class="seamTextUnorderedListItem">Questionnaire</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">A mammogram is a breast cancer screening procedure involving taking an x-ray picture of the breast.</li> <li class="seamTextUnorderedListItem">Contrast enhanced spectral mammograms (CESM) are similar to standard mammograms, but they include an intravenous (by vein) injection of contrast, which makes tissue and blood vessels more visible in scans.</li> <li class="seamTextUnorderedListItem">For CESMs, 2 images are taken almost at the same time after the contrast is given. The first image is similar to a regular mammogram. The second image shows areas that take up the contrast and show increased blood flow, which may indicate an area of concern.</li> <li class="seamTextUnorderedListItem">CESM is FDA approved for breast cancer detection, but its use is low.</li> <li class="seamTextUnorderedListItem">CESM is used most often when additional information is needed after a standard mammogram.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04904757' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.mdanderson.org/cancerwise/what-is-a-contrast-enhanced-mammogram.h00-159701490.html' target='_blank'>MD Anderson Cancer Center: What is a Contrast-Enhanced Mammogram?</a> </li></ul>
See more
34

NEAREST SITE: 2383 miles
Mayo Clinic Breast Clinic
Jacksonville,FL

VISITS: 1-2 visits

PHASE: NA

NCT ID: NCT06512350

Breath Samples to Detect Breast Cancer

Using Infrared Spectroscopy to Analyze Volatile Organic Compounds in the Breath of Patients With Breast Cancer Scientific Title

Purpose
To study if breath samples help detect breast cancer and if there are substances in the breath that are associated with breast cancer.
Who is this for?
Women 40-74 years old with dense breasts who are planning to receive a standard of care biopsy or MRI scan. You must not have been diagnosed with breast cancer.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Breathe into a device, 1-2 times</li> <li class="seamTextUnorderedListItem">Questionnaires</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Researchers will collect breath samples before your biopsy or MRI scan.</li> <li class="seamTextUnorderedListItem">If your biopsy or MRI scan results in a breast cancer diagnosis, a second sample will also be collected after treatment.</li> <li class="seamTextUnorderedListItem">This trial is also available in Spanish and French.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06512350' target='_blank'>ClinicalTrials.gov</a> </li></ul>
See more
35

NEAREST SITE: 2395 miles
Moffitt Cancer Center
Tampa,FL

VISITS: 1-2 times in 6 months

PHASE: II

NCT ID: NCT06833502

CT Scan to Detect Metastasis for Stage I-III Node Positive Breast Cancer

Phase II Study of Systemic Screening in Pathologic Node Positive Breast Cancer Following Neoadjuvant Chemotherapy and Surgery Scientific Title

Purpose
To use CT scans to determine how often node positve breast cancer spreads outside of the breast (metastasis) after chemotherapy and surgery.
Who is this for?
People with stage I, stage II, or stage III node positive breast cancer. You must have received at least 2 months of doxorubicin (Adriamycin®), paclitaxel (Taxol®), or docetaxel (Taxotere®) before surgery (neoadjuvant) and surgery.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">CT scan, 1-2 times</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Node positive breast cancer is breast cancer that has spread to the lymph nodes.</li> <li class="seamTextUnorderedListItem">A computed tomography (CT) scan produces body pictures created by x-ray energy.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06833502' target='_blank'>ClinicalTrials.gov</a> </li></ul>
See more
36

NEAREST SITE: 2406 miles
University of North Carolina
Chapel Hill,NC

VISITS: 2 visits in 8 months

PHASE: NA

NCT ID: NCT06789653

Studying Brain and Heart Changes During Chemotherapy for Women with Stage I-III Breast Cancer

Investigating Cellular Senescence and Organ Aging in Breast Cancer Patients Undergoing Adjuvant Chemotherapy: A Novel Approach Utilizing Organ Specific Age Proteomics Scientific Title

Purpose
To study brain and heart changes before and after chemotherapy.
Who is this for?
Women 22-65 years old with stage I, stage II, or stage III breast cancer who are planning to receive chemotherapy. You must be receiving care at UNC Lineberger Comprehensive Cancer Center.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will provide the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Blood samples, 2 times in 8 months</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">People receiving chemotherapy often have heart and thinking problems (cognition).</li> <li class="seamTextUnorderedListItem">Information from this study may help doctors in the future identify people at the highest risk for these problems and make treatment decisions.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06789653' target='_blank'>ClinicalTrials.gov</a> </li></ul>
See more
37

NEAREST SITE: 2436 miles
George Washington University Cancer Center
Washington D.C.,DC

VISITS: Coincides with routine care

PHASE: NA

NCT ID: NCT06483997

Studying Diet, Blood Health, and Chemotherapy Dosing for Women with Stage I-III Breast Cancer

Associations Between Diet, Hepcidin, and Relative Dose Intensity Among Women Receiving Chemotherapy for Breast or Gynecological Cancer Scientific Title

Purpose
To study the relationship between diet, blood proteins, and chemotherapy dosing.
Who is this for?
Women with stage I, stage II, or stage III breast cancer who are planning to receive chemotherapy at George Washington University Cancer Center.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will complete the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Provide blood samples</li> <li class="seamTextUnorderedListItem">Complete surveys about diet</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">The diet a person consumes before chemotherapy may affect blood proteins, blood health, and the ability to receive chemotherapy as recommended.</li> <li class="seamTextUnorderedListItem">This study is also enrolling people with other types of cancer.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06483997' target='_blank'>ClinicalTrials.gov</a> </li></ul>
See more
38

NEAREST SITE: 2437 miles
Adventhealth
Orlando,FL

VISITS: Number of visits unavailable

PHASE: NA

NCT ID: NCT07231159

Understanding Barriers to Follow-Up After a Positive Breast Cancer Screening Result

Building on Trust: Navigating Preventive Lung, Breast, and Prostate Cancer Screenings at Community Resource Spots Scientific Title

Purpose
To study a community-based outreach program for screening, diagnosis, and treatment of breast cancer.
Who is this for?
Women, age 40-74 years, who received a result of "positive" for breast cancer following screening.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Referral for follow-up after receiving a <q>positive</q> breast cancer screening result</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">This study is looking at differences between adults who accept or decline follow-up after a <q>positive</q> cancer screening result. The researchers are looking for factors that prevent or make it easier for someone to receive cancer screening, diagnosis, treatment, and clinical trial screening. They are also seeking to understand people's feelings towards navigators who may help people receive these services.</li> <li class="seamTextUnorderedListItem">This trial is enrolling people who were screened for other cancers.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT07231159' target='_blank'>ClinicalTrials.gov</a> </li></ul>
See more
39

NEAREST SITE: 2444 miles
Burnett School Biomedical Sciences
Orlando,FL

VISITS: 1 visit

PHASE: NA

NCT ID: NCT06068257

Blood Test to Detect Breast Cancer

Translational Utility of Tumor-Derived FGF19 in a Novel Blood-Based Endocrine Suppression Approach Scientific Title

Purpose
To help develop a blood test to detect breast cancer.
Who is this for?
People with stage 0 (DCIS), stage I, stage II, stage III, or stage IV (metastatic) breast cancer and people who have not been diagnosed with breast cancer.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">1 fasting blood draw</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Biomarkers are genes, molecules, or other features in a person that tell doctors something about that person’s health.</li> <li class="seamTextUnorderedListItem">FGF19 is a protein that is a possible biomarker for breast cancer. The amount of FGF19 in blood may be abnormal in people with breast cancer.</li> <li class="seamTextUnorderedListItem">The study will compare the amount of FGF19 in the blood of people with and without breast cancer.</li> <li class="seamTextUnorderedListItem">This study is also enrolling people with other types of cancer.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06068257' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/about-cancer/diagnosis-staging/diagnosis#:~:text=Complete%20blood%20count%20(CBC)&text=It%20can%20help%20diagnose%20some,health%20during%20and%20after%20treatment.' target='_blank'>National Cancer Institute: How Cancer Is Diagnosed</a> </li><li class='seamTextUnorderedListItem'><a href='https://med.ucf.edu/media/2023/03/Participant-Recruitment-Flyer-External_Version-1_Tumor-Derived-FGF19_PI-Deborah-Altomare.pdf' target='_blank'>UCF Study Information</a> </li></ul>
See more
40

NEAREST SITE: 2539 miles
Memorial Sloan Kettering Basking Ridge (All Protocol Activities)
Basking Ridge,NJ

VISITS: Number of visits unavailable

PHASE: NA

NCT ID: NCT06334354

Changes in Thinking and Memory Over Time for Women with Stage I-III Breast Cancer After Treatment

Cognitive Aging in Older Long-term Breast Cancer Survivors (TRAC) Scientific Title

Purpose
To study how differences in mental function develop over time in breast cancer survivors compared to people without a history of cancer.
Who is this for?
Women 65-80 years old with stage I, stage II, or stage III breast cancer who were diagnosed between 55-60 years old (5-25 years ago) and have completed treatment, and people who do not have a history of breast cancer.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Online surveys</li> <li class="seamTextUnorderedListItem">Saliva (spit) sample, by mail</li> <li class="seamTextUnorderedListItem">Urine sample</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Problems with thinking such as problems with memory, attention, and information processing may occur in people who were previously treated for breast cancer compared to those without a history of cancer.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06334354' target='_blank'>ClinicalTrials.gov</a> </li></ul>
See more
41

NEAREST SITE: 2554 miles
Hackensack Meridian Health
Totowa,NJ

VISITS: 1 visit

PHASE: NA

NCT ID: NCT07038785

Identification of Breast Cancer in Breath Samples By Trained Detection Dogs for Women Planning to Receive Breast Cancer Screening or Biopsy

A Double Blind Observational Study to Validate the SpotitEarly Test for the Detection of Breast Cancer (The PINK Study) Scientific Title

Purpose
To study whether trained detection dogs and artificial intelligence (AI) can identify breast cancer in a person's breath.
Who is this for?
Women planning to receive routine breast cancer screening (mammogram, ultrasound scan, MRI scan) or a breast biopsy.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Provide a breath sample by breathing into a surgical mask</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Specially trained dogs may be able to smell breast cancer in a person's breath.</li> <li class="seamTextUnorderedListItem">You may also be asked to provide breath samples at home for up to 2 years.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT07038785' target='_blank'>ClinicalTrials.gov</a> </li></ul>
See more
42

NEAREST SITE: 2574 miles
Montefiore Medical Center
The Bronx,NY

VISITS: 1 visit

PHASE: NA

NCT ID: NCT03694756

Experimental Breast MRI Scan for People with Suspected Breast Cancer or Stage I-III Breast Cancer

TMEM-MRI: A Pilot Feasibility Study of Magnetic Resonance Imaging for Imaging of TMEM (Tumor Microenvironment of Metastasis) in Patients With Operable Breast Cancer Scientific Title

Purpose
To study the ability of TMEM-MRI, an experimental type of MRI scan, to detect breast cancer cells.
Who is this for?
People with a breast mass that is suspected to be breast cancer, or people with stage I, stage II, or some stage III breast cancer who have not yet received treatment.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">TMEM-MRI scan, 1 time</li> <li class="seamTextUnorderedListItem">Contrast agent, by IV, 1 time</li> <li class="seamTextUnorderedListItem">Biopsy (if you have not yet received one)</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">A magnetic resonance imaging (MRI) scan produces body pictures created by using magnetic energy rather than x-ray energy.</li> <li class="seamTextUnorderedListItem">Tumor Microenvironment of Metastasis - Magnetic Resonance Imaging (TMEM-MRI) scans are an experimental type of MRI scan that can detect tumor areas that are more likely to travel to other sites in the body.</li> <li class="seamTextUnorderedListItem">TMEM-MRI scans may be useful to identify tumors with a higher chance of coming back (recurrence) after treatment.</li> <li class="seamTextUnorderedListItem">TMEM-MRI scans may also be useful for studying the response to neoadjuvant (before surgery) treatment such as chemotherapy and hormone therapy.</li> <li class="seamTextUnorderedListItem">A contrast agent, also called a tracer, is a radioactive substance that can look for and attach to cancer cells.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03694756' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/screening-testing/breast-mri' target='_blank'>Breastcancer.org: Breast MRI</a> </li></ul>
See more
43

NEAREST SITE: 2619 miles
Dartmouth-Hitchcock Medical Center
Lebanon,NH

VISITS: 1 visit

PHASE: NA

NCT ID: NCT06400563

MRI Scan with Wearable Device to Improve Breast Cancer Detection

Evaluation of the Magnetic Resonance-guided (MRg) Near-infrared Spectroscopy (NIRS) Imaging System Platform in Breast Cancer Patients Scientific Title

Purpose
To study if using a wearable device during MRI scans improves the ability to take breast images and detect breast cancer.
Who is this for?
Women newly diagnosed with stage I, some stage II, or some stage III breast cancer who have not yet received surgery.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">MRI scan with wearable device</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">A magnetic resonance imaging (MRI) scan produces body pictures created by using magnetic energy rather than x-ray energy.</li> <li class="seamTextUnorderedListItem">The wearable device is attached to the breast using an adhesive nipple cover and breast tape.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06400563' target='_blank'>ClinicalTrials.gov</a> </li></ul>
See more
44

NEAREST SITE: 2626 miles
Cheshire Medical Center
Keene,NH

VISITS: 3 visits within 1 month

PHASE: NA

NCT ID: NCT06522568

Virtual Mammogram Decision Tool for Healthy Women Age 39-49 Years

Toward Optimization of a Mammography Decision Aid and Clinician Communication Intervention Trial for Rural Settings Scientific Title

Purpose
To study the effectiveness of a virtual breast cancer screening decision aid called MyMammogram.
Who is this for?
Women, age 39-49 years, who are planning to visit their primary care doctor in the next month. You must not have breast cancer or have had a mammogram in the last year.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will be randomly assigned to 1 of 3 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1: Experimental</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Use MyMammogram before doctor's appointment</li> <li class="seamTextUnorderedListItem">Surveys, 3 times</li> <li class="seamTextUnorderedListItem">Interview</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2: Experimental</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Use MyMammogram before doctor's appointment</li> <li class="seamTextUnorderedListItem">Your doctor will receive information from MyMammogram about your breast cancer risk</li> <li class="seamTextUnorderedListItem">Surveys, 3 times</li> <li class="seamTextUnorderedListItem">Interview</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 3: Usual Care</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">No intervention</li> <li class="seamTextUnorderedListItem">Surveys, 3 times</li> <li class="seamTextUnorderedListItem">Interview</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">MyMammogram is a virtual education tool that can help you learn about your breast cancer risk and the role of mammograms in screening for breast cancer.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06522568' target='_blank'>ClinicalTrials.gov</a> </li></ul>
See more
45

NEAREST SITE: 2652 miles
UMass Medical School
Worcester,MA

VISITS: 1 visit

PHASE: NA

NCT ID: NCT05968157

Breast MRI Scans for Women at High Risk for Breast Cancer

MIRAI-MRI: Comparing Screening MRI for Patients at High Risk for Breast Cancer Identified by Mirai and Tyrer-Cuzick Scientific Title

Purpose
To study the use of MIRAI model (guidelines) to identify breast cancer risk.
Who is this for?
Women who are at high risk for breast cancer who have received a mammogram.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Breast MRI scan using MIRAI</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Identifying breast cancer risk is important for making screening decisions.</li> <li class="seamTextUnorderedListItem">The standard way of identifying breast cancer risk is called the Tyrer-Cuzick model (guidelines).</li> <li class="seamTextUnorderedListItem">In this trial, the experimental way of identifying breast cancer risk is called the MIRAI model (guidelines), which uses a type of artificial intelligence (AI) to study mammograms.</li> <li class="seamTextUnorderedListItem">A magnetic resonance imaging (MRI) scan produces body pictures created by using magnetic energy rather than x-ray energy.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05968157' target='_blank'>ClinicalTrials.gov</a> </li></ul>
See more
 

Connect

BreastCancerTrials.org
499 Illinois Ave, Suite 200
San Francisco, CA 94158
(888) 282-7099
Help-Desk@bctrials.org
Follow us on
Twitter
Facebook

Site Map

Find a Trial
How BCT Matching Works
What You'll Need
Get Started
Making your Decision
- Questions for Doctors
- Questions for Researchers
- Financial Concerns
See All Trials
Why Participate
Why Trials are Important
Treatment Trials
Other Types of Studies
Myths & Facts
Your Rights
Personal Stories
Who We Are
About Us
Our Team
Supporters
BCT for Researchers
BCT for Care Providers
Our Newsletter
Get Involved
Contact Us
FAQs
BreastCancerTrials.org
Privacy Policy
Clinical Trials
Resources
Clinical Trial Glossary
Breast Cancer Drugs
Research Advocacy
Our Newsletter
Other Resources
© 2025 Quantum Leap Healthcare Collaborative.
 
All rights reserved. No portion of this website may be reproduced, copied, or in anyway reused without written permission from BreastCancerTrials.org
Design: HDSF